rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Michael Myers

Chief Executive Officer

Company insider

Files Form 4 as: Chief Executive Officer, Quoin Pharmaceuticals.

In numbers

Trades disclosed
17
Buys
4
Sells
0
Bought
$479K
Sold
$0
Companies
1
Companies where not an officer
0
First trade
26 Oct 2023
Last trade
31 Aug 2026
Last filed
1 Sep 2026

Companies traded

Where they are an officer
QNRX Quoin PharmaceuticalsDirector, Officer · Biotechnology · last 31 Aug 20264 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
31 Aug 2026filed 1 Sep 2026QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$100K20,490 at $4.88filing
31 Aug 2026filed 1 Sep 2026QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—10,245filing
31 Aug 2026filed 1 Sep 2026QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—10,245filing
31 Aug 2026filed 1 Sep 2026QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$100K20,490 at $4.88filing
4 Feb 2026filed 6 Feb 2026QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—318,750 at $0.00filing
4 Feb 2026filed 6 Feb 2026QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—318,750 at $0.00filing
29 May 2025filed 13 Jun 2025QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—42,857 at $0.00filing
29 May 2025filed 2 Jun 2025QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—42,039 at $0.00filing
23 Dec 2024filed 27 Dec 2024QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—555,556filing
23 Dec 2024filed 27 Dec 2024QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code P—555,556filing
23 Dec 2024filed 27 Dec 2024QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$250K555,556 at $0.45filing
9 Dec 2024filed 10 Dec 2024QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—536,603 at $0.00filing
4 Sep 2024filed 5 Sep 2024QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$3,5135,322 at $0.66filing
4 Sep 2024filed 5 Sep 2024QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$6,1508,200 at $0.75filing
4 Sep 2024filed 5 Sep 2024QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$19K23,572 at $0.80filing
3 Sep 2024filed 5 Sep 2024QNRX Quoin PharmaceuticalsBiotechnologySEC FORM 4 Bought$496800 at $0.62filing
26 Oct 2023filed 30 Oct 2023QNRX Quoin Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—80,965 at $0.00filing

News

Sectors

Health Care4

Buys in green, sells in red, by the company’s sector.

Related people

Anthony James CulverwellDirector · Director at Quoin Pharmaceuticals, filing Form 4 there in the last year
Denise P. CarterChief Operating Officer · Chief Operating Officer at Quoin Pharmaceuticals, filing Form 4 there in the last year
Sally Bridget LawlorChief Financial Officer · Chief Financial Officer at Quoin Pharmaceuticals, filing Form 4 there in the last year
Dennis LangerDirector · Director at Quoin Pharmaceuticals, filing Form 4 there in the last year
Michael T. SemberDirector · Director at Quoin Pharmaceuticals, filing Form 4 there in the last year